{"entity":{"id":"nct06499350","kind":"trial","name":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Tislelizumab in advanced solid tumours, run by FindCure Biosciences (ZhongShan) Co., Ltd., now recruiting.","summary":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06499350 by FindCure Biosciences (ZhongShan) Co., Ltd., with 33 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-01. Interventions recorded: FC084CSA+Tislelizumab combination (dose escalation) and RP2D of FC084CSA+Tislelizumab combination (dose expansion).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06499350","url":"https://clinicaltrials.gov/study/NCT06499350"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06499350","phase":"1/2","setting":"A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors","sponsor":"FindCure Biosciences (ZhongShan) Co., Ltd.","enrolled":33,"outcomes":[]},"route":"/trials/nct06499350/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}]}}